Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam RNAi IP Upheld in European Opposition Proceedings

Premium

Alnylam Pharmaceuticals said this week that its Tuschl II patent has been fully upheld by the European Patent Office in opposition proceedings.

The patent, EP 1407044, generally relates to compositions, methods, and uses of siRNAs capable of triggering an RNAi effect. Alnylam said that opponents to the patent included Merck subsidiary Sirna Therapeutics, Silence Therapeutics, Pfizer, and BASF.

"Tuschl II remains a very important and valuable patent in our overall broad estate of patents important for the development and commercialization of RNAi therapeutics, and a patent family to which we are the exclusive licensee," Alnylam President and COO Barry Greene said in a statement.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.